In rats fed a high-fat, high-cholesterol diet, two Lactiplantibacillus plantarum strains, LP5 and BX62, given alone or together, cut hepatic lipid accumulation, intestinal permeability, inflammation and liver injury markers. LP5 did more against weight gain and steatosis, linked to upregulated bile acid synthesis enzymes CYP7A1 and CYP8B1. BX62 gave extra protection against oxidative damage via the Nrf2-HO-1 pathway. All three treatments activated AMPK, suppressing lipogenic proteins (SREBP-1c, FASN, SCD1) and raising fatty acid oxidation proteins (PPARα, CPT1a).
This evidence comes from animals, and it should be read that way. Rodent NAFLD models driven by a high-fat, high-cholesterol diet routinely respond to probiotics, and many such findings fail to translate to people. The strain-specific split is the interesting part: pairing a cholesterol-handling strain with an antioxidant strain is a rational design, though the abstract reports no clear additive benefit from the combination over either strain alone. Mechanistic claims rest on protein expression rather than causal experiments, so the bile acid and Nrf2 attributions remain associations. Human data on probiotics for fatty liver are modest, with small trials showing small improvements in liver enzymes and little evidence on hard outcomes. Nothing here supports buying a product; these strains are not established as commercially available. Weight loss, diet quality and exercise remain the proven levers for fatty liver. Editorially, this is incremental preclinical work that adds mechanistic detail to a crowded field rather than shifting practice.